| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5712b4838bdb16ebbc41121239e165b9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-621
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D275-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D275-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
1978-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9791e0db2c4ffcfb3be67ff4d63139d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f1897b2dadba9a5817378b5e33ebad6 |
| publicationDate |
1979-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0001503-A1 |
| titleOfInvention |
Antithrombotic compositions containing benzisothiazolones |
| abstract |
This invention relates to a pharmaceutical composition useful in the treatment of arterial thrombosis. A combination of a non-steroidal anti-inflammatory agent with a benzisothiazolone of formula (I) is found to be capable of inhibiting the aggregation of blood platelets to a greater degree than each of the components separately.n R 1 and R 2 represent a variety of substituent groups; X represents a bond or an alkylene chain; and R represents a heterocyclic group. n When the anti-inflammatory agent contains a carboxylic acid group, the combination with compound (I) may be in the form of a salt. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5041430-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4673746-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115381827-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9104031-A1 |
| priorityDate |
1977-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |